PROBLEM

The immune system normally exists in a balanced state, but in the case of autoimmune disease, this balance is askew, and the therapeutic effort required to rebalance it can be complex.

SOLUTION

Pandion's technology is designed to create a suite of therapies for rebalancing the immune system.
 
 

What Makes Us Different

Modular Approach
Pandion’s approach to developing modular proteins, antibodies and bispecifics starts with cutting-edge immunomodulators that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses. We then combine these immunomodulators with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect.

Effectors
For the effectors — the component of our molecules that deliver the biologic effect — we have focused initially on T cell modulators. With this design, we are developing biologics that engage pathways that activate regulatory T cells (Treg) or inhibit overactive pathogenic T cells. Recent discovery efforts have expanded our effector technology to include broad-acting pathway modulators which will permit us to modulate multiple cell types with a single mechanism in a tissue-targeted manner.

Tissue-selective Tethers
Our modular approach can include the addition of tissue-selective tethers to our immunomodulators, enabling the selective targeting of distinct cellular locations within a given tissue. With tissue-selective tethers, we can fine tune the delivery of our potent immunomodulators to exactly the place where they can provide most therapeutic benefit.

Our approach to developing modular proteins, antibodies and bispecifics starts with immunomodulators ("effectors") that work systemically by activating regulatory pathways that suppress uncontrolled autoimmune responses. We then combine these effectors with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect.
1 2 3
 
We first select an effector protein...
Which is combined with an Fc region...
If desired for a local effect, we add a tissue-specific tether.
Back to Top